

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1430 Alexascins, Virginia 22313-1450 www.nepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,190	12/20/2006	Pablo Vicente Escriba Ruiz	U 016243-8	7142
LADAS & PA	7590 11/18/200 RRY LLP	9	EXAMINER HENLEY III, RAYMOND J	
26 WEST 61S	Γ STREET			
NEW YORK,	NY 10023		ART UNIT	PAPER NUMBER
			1614	
			NOTIFICATION DATE	DELIVERY MODE
			11/18/2000	ET ECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

nyuspatactions@ladas.com

Application No. Applicant(s) 10/575,190 ESCRIBA RUIZ PABLO VICENTE Office Action Summary Examiner Art Unit Raymond J. Henley III 1614 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 18 September 2009. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 9-19 is/are pending in the application. 4a) Of the above claim(s) 9-19 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)

Paper No(s)/Mail Date

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (FTO/SB/08)

Paper No(s)/Mail Date.

6) Other:

5) Notice of Informal Patent Application.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	
10575190	12/20/06	ESCRIBA RUIZ PARLO VICENTE	II 016243-8

12/20/06 ESCRIBA RUIZ PABLO VICENTE II 016243-8

FYAMINER

Raymond J. Henley III ART LINIT PAPER

20091113

DATE MAILED:

1614

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

NOTICE OF NON-RESPONSIVE AMENDMENT

Applicant's amendment filed September 18, 2009 has been received and entered into the application. Accordingly, claims 1-8 have been cancelled and claims 9-19 have been added

ELECTION BY ORIGINAL PRESENTATION

Applicants have added new claims 9-19 and cancelled original claim 1-8, which were directed to uses for several purposes, None of newly presently claims directed mirror the originally present claims, and thus cannot be examined.

Newly submitted claims 9-19, are thus directed to an invention that is independent or distinct from the invention originally claimed, (see previous Office action for the Examiner's interpretation of the claims).

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 9-19, all claims pending, are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1,142(b) and MPEP § 821.03.

Applicants are provided one (1) month to respond to the present Office action by presenting method-type claims which are consistent with those already presented. Insofar as the previous claims were "USE" claims, and thus non-statutory, the statements in the claims as to an intended use were not given patentable weight. Should Applicants respond to this communication by adding method claims directed to patentably distinct therapeutic objectives, consideration by the Examiner will be given in determining if a restriction requirement is proper. In order to expedite prosecution, Applicants are urged to present method claims directed to a single type of therapeutic objective.

> /Raymond J Henley III/ Primary Examiner Art Unit: 1614

LADAS & PARRY LLP

26 WEST 61ST STREET NEW YORK, NY 10023